CRITICAL REVIEW OF PHARMACOGENOMICS IN ANTIPARKINSONIAN DRUG THERAPY: IMPACT ON CLINICAL MANAGEMENT OF PARKINSON'S DISEASE
DOI:
https://doi.org/10.22159/ajpcr.2016.v9i6.13350Abstract
Parkinson's disease is a progressive neurodegenerative disorder characterized by rest tremors, bradykinesia , rigidity , postural instability , gait dysfunction and several non motor symptoms . The marked difference in drug response and adverse effect profile among patients led to search of genetic markers and polymorphism associated with response to antiparkinsonian drugs which will enable us to predict an individuals  response to drugs in terms of both efficacy and toxicity. Hence efforts to define the role of genetic polymorphism in optimizing pharmacotherapy of Parkinson's disease have been undertaken and some promising genetic loci for the treatment have been determined. Therefore we aim to present a critical review of pharmacogenetic aspects of levodopa , dopamine agonists and COMT inhibitors and describe gene polymorphism of interest for future research.
Â
Downloads
References
Factor SA. Current status of symptomatic medical therapy in Parkinson’s disease. Neurotherapeutics. 2008;5(2):164–80.
Vesell ES. Pharmacokinetic perspectives gained from twin and family studies. Pharmacol Ther. 1989;41(3):535–552.
Kalow W, Thang BK, Endreyi L. Hypothesis: comparisons of inter and intra-individual variations can substitute for twin studies in drug research. Pharmacokinetics. 1998;8(4):283–289
Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409(6822):928–933.
EvansWE, RellingMV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004; 429(6990):464–468.
Haydeh Payami et al. Promise of Pharmacogenomics for Drug Discovery, Treatment and Prevention of Parkinson’s Disease. A Perspective. Neurotherapeutics. 2014 Jan; 11(1): 111–116.
Vallone D, Picetti R, Borrelli E (2000) Structure and function of dopamine receptors. Neurosci Biobehav Rev 24:125–132.
Rondou P, Haegeman G, Van Craenenbroeck K (2010) The dopamine D4 receptor: biochemical and signalling properties. Cell Mol Life Sci 67:1971–1986.
Jean Martin Beaulieu , Raul R Gainetdinov. The Physiology, Signaling, and Pharmacology of Dopamine Receptors. Pharmacological Reviews . March 2011 63:182-217
Lee S P, So C H, Rashid A J, Varghese G, Cheng R, Lanca A J, O'Dowd B F, George S R. Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal. J. Biol. Chem.2004;279(34):35671–35678.
Wang J, Liu Z L, Chen B. Association study of dopamine D2 D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology. 2001;56(12):1757–1759.
Sokoloff P, Giros B, Martres M P, Bouthenet M L, Schwartz J C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990;347 (6289):146–151.
Hassan A et al. Association of Parkinson disease age of onset with DRD2, DRD3 and GRIN2B polymorphisms. Parkinsonism Relat Disord. 2016 Jan; 22:102-5.
Van Tol H H, Wu C M, Guan H C, Ohara K, Bunzow J R, Civelli O, Kennedy J, Seeman P, Niznik H B, Jovanovic V. Multiple dopamine D4 receptor variants in the human population. Nature. 1992;358 (6382):149–152.
Brian J. Ciliax etal . The Dopamine Transporter: lmmunochemical Characterization and Lo calization in Brain . The Journal of Neuroscience, March 1995, 75(3): 1714-1723
Kaiser R, Hofer A, Grapengiesser A, Gasser T, Kupsch A, Roots I, Brockmoller J. L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology. 2003;60 (11):1750–1755.
Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995;34 (13):4202–4210
Contin M et al. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease. Movement Disorders. 2005 Jun;20(6):734-9.
Schumacher Schuh A Fet al. Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients. Pharmacogenomics J. 2014 Jun;14(3):289-94.
Matthijs L Becker et al. OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users . Neurogenetics. 2011 Feb; 12(1): 79–82.
Ruottinen H M , Rinne U K . COMT inhibition in the treatment of Parkinson's disease. J Neurology. 1998 Nov;11(3) 25-34.
D J Brooks. Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;68:685-689
Maurits E L Arbouw et al. Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease. European J Clincal Pharmacology. 2009 Dec; 65(12): 1245–1251.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
